Evidence, Access & Pricing
Value
We support our clients to develop and communicate a clear value strategy that is supported by compelling evidence.
Home / Services / Evidence, Access & Pricing / Value
Providing the right evidence to payers and other key access stakeholders is essential to unlock the pricing and access potential of therapies (new and on-market). Working across the product lifecycle, and by leveraging our deep and long-standing experience with payers and other stakeholders, Trinity experts can help clients to:
- Identify the most impactful target value story for your therapy
- Determine the key evidence gaps that need to be prioritized
- Design an evidence-generation roadmap and studies to address these gaps
- Develop compelling materials to educate access stakeholders pre-launch and post-launch
- Present the value story and supporting evidence to justify price decisions
- Support the development of AMCP and global value dossiers, as well as their local adaptations
Latest Evidence, Value, Access and Pricing Intelligence
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
The Implementation Game: The Inflation Reduction Act Medicare Drug Price Negotiation Program Guidance
Trinity’s Take Introduction Since the Inflation Reduction Act (IRA) was signed into law in August 2022, biopharma stakeholders have noted the high likelihood of the legislation being challenged in court alongside many questions about how some of the new CMS programs would function. The Medicare Drug Price Negotiation Program is one IRA program expected to […]
Generating Robust Insights to Develop a Compelling Value Story with RWE
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization […]
Meet Our Value Experts
Monica Martin de Bustamante
Senior Partner &
Head of Advisory
Monica’s career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the mature and emerging markets, with deep expertise in the U.S., EU5, CAN and JPN. Monica has worked across the major therapeutic areas (oncology, cardiovascular, neurology, metabolic, autoimmune, gastrointestinal, respiratory, etc.) collaborating […]
Valeria Boers Trilles
Director,
Value, Access & Pricing
Ms. Boers is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Ms. Boers was part of the CBPartners team and focused her experience on pricing and market access engagements, proving strategic support to optimize value communication, product positioning, IRP-based launch sequence and pricing opportunity across a range of therapeutic areas, […]
Christian Frois
Partner,
Value, Access & Pricing
Christian is a recognized and widely published expert on pricing, contracting, market access and payer evidence strategy. He leads Trinity’s pricing, market access, reimbursement and contracting (PARC) group, and has supported the development of PARC strategies for more than 50 assets in the US and ex-US.
Andrew Gould
Partner,
Value, Access & Pricing
Andrew is a Partner in Trinity’s Value, Access and Pricing practice and has over 15 years working within the Life Sciences arena. Prior to joining Trinity, he led CBPartners’ U.S. Center of Excellence and focused on managed markets strategy engagements. His experience has emphasized the development of numerous pricing and access strategies for both pre-launch […]
John Greenaway
Partner,
Value, Access & Pricing
John has 25 years of consulting experience and is currently a leadership team member within Trinity’s Evidence, Value, Access and Pricing (EVAP) practice. John is an expert in U.S. Reimbursement and Contracting where he focuses on Market Access Strategy through Managed Care and Provider / GPO Contract Strategies and sustainable contract structure and design. In […]
Nandini Hadker
Partner,
Evidence Strategy
An economist by training, Nandini is a Partner at Trinity Life Sciences with over two decades of experience in custom research and strategy consulting. She is an expert at helping clients identify what real-world evidence will “move the needle” and drive their product’s success, generating that evidence using publication-grade research, and pulling the insights through […]
Max Hunt
Partner,
Value, Access & Pricing
Max is a Partner in Trinity’s Evidence, Value, Access and Pricing (EVAP) practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases and cell and gene therapies. Over the last decade, Max’s work has spanned a […]
Miguel Martín de Bustamante
Partner,
Value, Access & Pricing
Prior to joining Trinity, Mr. Martín de Bustamante worked across CBPartners’s practices, with a focus on Value, Access, and Pricing. He developed expertise across many related areas, including innovative contracting and access models, strategic product / portfolio positioning, IRP and commercial opportunity based launch sequencing, as well as value positioning across various therapeutic areas. He […]
Matt O’Hara
Partner,
Evidence Strategy
Matt joins Trinity with over 20 years of life sciences consulting experience. During his career, Matt has worked with both pharmaceutical and medical device clients across business/commercial strategy (pricing, market access, product portfolio rationalization, acquisitions, Intellectual Property, and market insights), HEOR (value proposition development, evidence generation planning, and literature reviews, budget impact and comparative effectiveness […]
Bami Oshinowo
Partner, Value, Access & Pricing
& London Office Lead
Prior to joining Trinity, Ms. Oshinowo led engagement work within the Value, Access and Pricing Practice and drove the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA […]
Shinkyu Park
Director,
Evidence, Value, Access & Pricing
Mr. Park is a Director in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Mr. Park’s work at CBPartners was primarily focused on pricing, market access, and value demonstration engagements in support of strategic planning with a variety of biopharmaceutical clients. Mr. Park has led many global (including USA, EU, APAC and LatAm) […]
Julia Pikus
Principal,
Value, Access & Pricing
Julia is a Principal in Trinity’s Value, Access & Pricing practice. Prior to joining Trinity, Julia led engagement work within the Value, Access and Pricing Practice and drove the Cell and Gene Therapy Centre of Excellence at CBPartners. In this capacity, she supported a range of qualitative and quantitative engagements to inform current and future […]
Greg Berzolla
Managing Director
Greg is a Managing Director in Trinity’s Evidence, Value, Access and Pricing practice, leading the Access Analytics team. Prior to joining Trinity, Greg was a Senior Vice President at Precision, Value and Health. Greg has 30+ years of healthcare consulting and industry experience, including ~20 years of market access and commercial strategy experience. He has […]
Mary Fletcher-Louis
Managing Director &
Head of Value COE
Mary brings over 25 years of healthcare and consulting experience to Trinity. Fostering a culture of innovation in all her endeavors, Mary is currently pioneering the integration of health equity into life science value strategy. As a senior thought leader in the industry, Mary has held leadership roles in various domains including global market access, […]
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.